PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib

PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib

BackgroundImmunotherapy plays a crucial role in the treatment of tumors. However, few studies have investigated the relationship between the expression of Programmed Cell Death Ligand 1 (PD-L1, CD274) in microvascular endothelial cells (MECs), including blood endothelial cells (BECs) and lymphatic e...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yingfang Feng, Yuan Gao, Shaochuan Liu, Tingting Qin, Yan Zhang, Jing Wang, Kai Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Oncology
Subjects:	anlotinib PD-L1 microvascular endothelial cells immune checkpoints melanoma
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1544278/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy of PD-(L)1 inhibitors plus anlotinib in the second-line treatment of extensive-stage small cell lung cancer
by: Jian Zhang, et al.
Published: (2025-07-01)

Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature
by: Yuanhang Wang, et al.
Published: (2024-12-01)

Penpulimab and Anlotinib in PDL1 high-expression pulmonary giant cell carcinoma with cerebral metastases: case report and review
by: Minghong Xie, et al.
Published: (2024-12-01)

The Efficacy and Safety of Albumin‐Bound Paclitaxel Combined With Anlotinib and PD‐1/L1 Inhibitors For Treating Patients With Extensive‐Stage Small Cell Lung Cancer and Brain Metastasis: A Retrospective Cohort Study
by: Xiaobing Li, et al.
Published: (2024-12-01)

Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases
by: Hai-Zhen Yi, et al.
Published: (2025-07-01)

Anlotinib combined with penpulimab in the treatment of advanced adult thoracic spinal osteosarcoma: a case report
by: Xiaochun Chen, et al.
Published: (2025-07-01)

Monitoring Pseudoprogression Using Circulating Small Extracellular Vesicles Expressing PD‐L1 in a Melanoma Patient Treated With Immune Checkpoint Inhibitors
by: Charlée Nardin, et al.
Published: (2025-06-01)

Microvascular endothelial dysfunction in vascular senescence and disease
by: Daniel A. Kasal, et al.
Published: (2025-02-01)

Safety and efficacy of rechallenge with immune checkpoint inhibitors and anlotinib in advanced non-small cell lung cancer without targetable driver mutations: a retrospective analysis
by: Xinrong Chen, et al.
Published: (2025-05-01)

Pinitol Improves Lipopolysaccharide-Induced Cellular Damage in Human Dermal Microvascular Endothelial Cells
by: Min Young Go, et al.
Published: (2025-03-01)

Glutamate activates the MAPK pathway by inhibiting LPAR1 expression and promotes anlotinib resistance in thyroid cancer
by: Bin Liu, et al.
Published: (2025-06-01)

Successful treatment of advanced Birt-Hogg-Dubé syndrome-associated renal cell carcinoma with sarcomatoid dedifferentiation using anlotinib combined with PD-1 inhibitor after first-line therapy failure: a case report
by: Liqi Yi, et al.
Published: (2025-07-01)

Anlotinib induced type 1 diabetes: a case report
by: Jing Chen, et al.
Published: (2025-04-01)

Risk Factors for Prognosis of Lung Cancer Patients Receiving Anlotinib Treatment: A Retrospective Cohort Study
by: Congyi Xie, et al.
Published: (2025-02-01)

The efficacy and safety of anlotinib plus PD-1 inhibitor in locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) patients who progressed on prior immune checkpoint inhibitors (ICIs): a retrospective real-world study (NCT 04984096)
by: Xueru Zhu, et al.
Published: (2025-12-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
by: Amjad Zafar, et al.
Published: (2024-11-01)

Physiological shear stress suppresses apoptosis in human pulmonary microvascular endothelial cells
by: Simin Yan, et al.
Published: (2025-03-01)

Endothelial PD‐1 Regulates Vascular Homeostasis and Oligodendrogenesis during Brain Development
by: Tingting He, et al.
Published: (2025-04-01)

Optimizing Immunotherapy: The Synergy of Immune Checkpoint Inhibitors with Artificial Intelligence in Melanoma Treatment
by: Mohammad Saleem, et al.
Published: (2025-04-01)

MEK inhibitor PD0325901 upregulates CD34 expression in endothelial cells via inhibition of ERK phosphorylation
by: Chihiro Hosoda, et al.
Published: (2024-06-01)

Tumor Cavitation with Anlotinib Treatment in Lung Adenocarcinoma
by: Jie Huang, et al.
Published: (2025-05-01)

N6‐Methyladenosine modification mediated by METTL3 promotes DNA‐PKcs expression to induce anlotinib resistance in osteosarcoma
by: Yining Zhang, et al.
Published: (2025-02-01)

Long-term efficacy and updated survival outcomes of sintilimab plus anlotinib in patients with PD-L1-positive recurrent or metastatic cervical cancer
by: Jing Liu, et al.
Published: (2025-07-01)

PROGNOSTIC VALUE OF ENDOTHELIAL DYSFUNCTION IN CORONARY AND BRACHIAL ARTERIES, AND COMMON RISK FACTORS IN DEVELOPMENT OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH MICROVASCULAR ANGINA
by: G. N. Soboleva, et al.
Published: (2017-03-01)

Identification of novel PD-1/PD-L1 small molecule inhibitors: virtual screening, synthesis and in vitro characterisation
by: Tingting Wu, et al.
Published: (2024-12-01)

RAF1 promotes anlotinib resistance in non-small cell lung cancer by inhibiting apoptosis
by: Shuo Wu, et al.
Published: (2025-04-01)

Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial
by: Xiangrui Meng, et al.
Published: (2025-06-01)

Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer: A Retrospective Exploratory Study
by: Chen TF, et al.
Published: (2025-06-01)

N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1
by: Bar Kaufman, et al.
Published: (2025-05-01)

Anlotinib-associated pulmonary embolism in brainstem glioblastoma treatment: a case report
by: Jia-Lan Zhao, et al.
Published: (2025-04-01)

Prevalencia de angina microvascular en pacientes del Centro de Investigaciones Médico Quirúrgicas
by: Lázaro Isralys Aldama Pérez, et al.

Efficacy and safety of postoperative adjuvant HAIC with FOLFOX combining PD-1 inhibitors in HCC patients with microvascular invasion: a propensity score matching analysis
by: Yuxin Liang, et al.
Published: (2025-03-01)

Sulodexide alleviates high glucose-induced cardiac microvascular endothelial cell injury in rat by activating the AMPK/SIRT1 pathway
by: GAO Yanli, et al.
Published: (2024-07-01)

ZEB1 transcription factor induces tumor cell PD-L1 expression in melanoma
by: Chloé Wirbel, et al.
Published: (2025-03-01)

Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD–1/PD‐L1 Inhibitors
by: Green Hong, et al.
Published: (2025-04-01)

Ezrin is essential for the entry of Japanese encephalitis virus into the human brain microvascular endothelial cells
by: Yan-Gang Liu, et al.
Published: (2020-01-01)

Production of Antibodies Binding Murine Nuclear PD-L1
by: Valentina Kostenko, et al.
Published: (2024-04-01)

Systematic literature review of real-world evidence on overall survival in cancer patients before and after the approval of anti-PD-(L)1 therapy
by: Dweeti Nayak, et al.
Published: (2025-08-01)

Differentiation status determines the effects of IFNγ on the expression of PD-L1 and immunomodulatory genes in melanoma
by: Teitur Sævarsson, et al.
Published: (2024-12-01)

Radiotherapy combined with anlotinib for refractory leiomyosarcoma: a case report and literature review
by: Ziming Li, et al.
Published: (2025-07-01)